Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lia Gore

Showing results (41-50 of 119) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2008
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomasLia Gore, Mace L Rothenberg, Cindy L O'Bryant, et al.
British Journal of Clinical Pharmacology|November 15, 2018
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignanciesYing Ou, Yang Xu, Lia Gore, et al.
Molecular Cancer Therapeutics|December 17, 2008
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumorsElaine T Lam, Cindy L O'Bryant, Michele Basche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working GroupLia Gore, S Percy Ivy, Frank M Balis, et al.
Pediatric Blood & Cancer|November 6, 2008
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerabilityLia Gore, Sant Chawla, Antonio Petrilli, et al.
Journal of the National Cancer Institute|March 26, 2026
FDA approvals for pediatric cancer indications using children's oncology group associated trials dataMargaret E Macy, Elizabeth Fox, Brenda J Weigel, et al.
American Journal of Hematology|June 4, 2014
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemiaLori A Gardner, Jelena Klawitter, Mark A Gregory, et al.
Investigational New Drugs|September 21, 2011
Phase I combination study of trabectedin and capecitabine in patients with advanced malignanciesLia Gore, E Rivera, M Basche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumorsRazelle Kurzrock, Amita Patnaik, Joseph Aisner, et al.
European Journal of Cancer (Oxford, England : 1990)|November 4, 2017
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanomaBirgit Geoerger, Christophe Bergeron, Lia Gore, et al.
Pageof 12

Showing results (41-50 of 119) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2008
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomasLia Gore, Mace L Rothenberg, Cindy L O'Bryant, et al.
British Journal of Clinical Pharmacology|November 15, 2018
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignanciesYing Ou, Yang Xu, Lia Gore, et al.
Molecular Cancer Therapeutics|December 17, 2008
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumorsElaine T Lam, Cindy L O'Bryant, Michele Basche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working GroupLia Gore, S Percy Ivy, Frank M Balis, et al.
Pediatric Blood & Cancer|November 6, 2008
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerabilityLia Gore, Sant Chawla, Antonio Petrilli, et al.
Journal of the National Cancer Institute|March 26, 2026
FDA approvals for pediatric cancer indications using children's oncology group associated trials dataMargaret E Macy, Elizabeth Fox, Brenda J Weigel, et al.
American Journal of Hematology|June 4, 2014
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemiaLori A Gardner, Jelena Klawitter, Mark A Gregory, et al.
Investigational New Drugs|September 21, 2011
Phase I combination study of trabectedin and capecitabine in patients with advanced malignanciesLia Gore, E Rivera, M Basche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumorsRazelle Kurzrock, Amita Patnaik, Joseph Aisner, et al.
European Journal of Cancer (Oxford, England : 1990)|November 4, 2017
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanomaBirgit Geoerger, Christophe Bergeron, Lia Gore, et al.
Pageof 12